Corporate Banner
Satellite Banner
Spectroscopy
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Conformetrix and AstraZeneca Sign Collaborative Agreement

Published: Thursday, April 26, 2012
Last Updated: Thursday, April 26, 2012
Bookmark and Share
First collaborative deal for Conformetrix.

Conformetrix Ltd and AstraZeneca have announced that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Conformetrix's technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states.

This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets.

This new information should improve the efficiency and quality of the lead identification, lead optimization and candidate selection stages of drug discovery programmes.

Under the terms of the two-year collaboration, the technology will also be used to determine the bioactive conformations of naturally occurring ligands as templates for drug library enhancement and hit identification.

Commenting on today's news, Conformetrix's CEO, Dr Sam Williams, said, 'Conformetrix is delighted that its first collaborative deal is with AstraZeneca, a company with a strong reputation in innovative science-led R&D. We believe that this deal provides important validation of our technology, which improves the quality and efficiency of drug discovery, reducing the number of molecules needed to find a drug and enhancing the likelihood of clinical success. The Conformetrix team is looking forward to working with our new partner on this exciting programme.'

Mike Snowden, Vice President and Head of Discovery Sciences, AstraZeneca, said: "We are excited to be working with Conformetrix. We believe their technology will provide a powerful addition to our hit identification and lead optimization approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline."

In addition to an undisclosed upfront payment, Conformetrix will receive research funding and be eligible for milestones as certain targets are met. The discovery programme will be managed by a joint AstraZeneca-Conformetrix research team.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Revealing the Secrets of 19th Century Fashion Industry
The dye industry of the 19th century was fast-moving and international, according to a state-of-the-art analysis of four purple dresses.
How Nanoparticles Damage Immune Cells
New evidence points to protein oxidation, a common means of molecular damage.
Single Molecule Detection of Contaminants, Explosives or Diseases
A technique that combines the ultrasensitivity of surface-enhanced Raman scattering (SERS) with a slippery surface invented by Penn State researchers will make it feasible to detect single molecules of a number of chemical and biological species from gaseous, liquid or solid samples.
Extracting Uranium from Seawater
An ultra-high-resolution technique used for the first time to study polymer fibers that trap uranium in seawater may cause researchers to rethink the best methods to harvest this potential fuel for nuclear reactors.
Innovation Boosts Study of Fragile Biological Samples
Researchers have found a simple new way to study very delicate biological samples – like proteins at work in photosynthesis and components of protein-making machines called ribosomes – at the atomic scale using SLAC's X-ray laser.
Clues for Battling Botulism
Scientists decipher details of deadly toxin's cloaking mechanism that could guide development of new vaccines, treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!